Canada Spends Logo

Explore our Budget 2026 analysis

Grant: Master's Award: Canada Graduate Scholarships

McMaster University

$17,500.00

The Role of Autoantibodies to Cytoskeletal Proteins in the Etiology of CNS Lupus

FY 2009-10

Summary
Systemic Lupus Erythematosus (SLE) is a progressive disorder that damages many organs in the human body including the brain. The major culprit involved in SLE is proposed to be the body's own immune system, which is usually protects us. However, in SLE, components of this defence system begin to attack the body's cells and tissue. Recently, it has been shown that antibodies, which play a major role in clearing pathogens from our body, may be responsible for damaging the brain in SLE patients. Unfortunately, it remains unknown what these antibodies are binding to and how they are destroying the brain. Previously, we found that mice developing lupus-like disease contain antibodies that target certain cytoskeletal proteins involved in maintaining cell shape and protecting the cell. We are interested in understanding whether antibodies to the cytoskeletal protein MAP-2 (microtubule-associated protein-2) may be responsible for damaging the brain and adversely affecting behavior in mice. First we will determine when these antibodies are detected in diseased mice. This will provide important information regarding when antibodies first appear and how their presence relates to brain damage and altered behavior. Next, in order to examine where these antibodies bind, they will be applied to different structures in brains from healthy lupus-prone mice. This will establish whether antibodies to MAP-2 bind in specific regions or diffusely throughout the brain. Lastly, to determine whether these anti-MAP-2 antibodies actually damage the brain, they will be administered directly into the brain of healthy mice. This will provide conclusive evidence whether antibodies to MAP-2 are indeed destroying the brain and causing behavioral dysfunction. These experiments aim to provide a better understanding of the mechanisms underlying neurologic and psychiatric problems in SLE patients. Such knowledge may help in designing novel treatments for SLE and other behavioral disorders.
Program
Master's Award: Canada Graduate Scholarships
Location
Ontario, Canada
Recipient Type
Academia
Type
Grant
Source
CIHR Funding Decisions Database

As published

Id
199672
Name
Kapadia Minesh
Region
Ontario
Country
Canada
Orgtype
Institution Paid; Research Institution
Instname2
Neurosciences, Mental Health and Addiction
Theme2
Biomedical
Prcname2
Canada Graduate Scholarships Master's Awards A
Projecttitle
The Role of Autoantibodies to Cytoskeletal Proteins in the Etiology of CNS Lupus
Programtype2
Studentship Programs
Orgnameinp2
McMaster University
Cihramount2
$17,500
Cihrequipment2
$0
Programname2
Master's Award: Canada Graduate Scholarships
Keyworddelim
Animal Model; Anxiety; Autoimmunity; Brain Damage; Brain-Reactive Antibodies; Neuropsychatric Disorders; Systemic Lupus Erythematosus
Abstract
Systemic Lupus Erythematosus (SLE) is a progressive disorder that damages many organs in the human body including the brain. The major culprit involved in SLE is proposed to be the body's own immune system, which is usually protects us. However, in SLE, components of this defence system begin to attack the body's cells and tissue. Recently, it has been shown that antibodies, which play a major role in clearing pathogens from our body, may be responsible for damaging the brain in SLE patients. Unfortunately, it remains unknown what these antibodies are binding to and how they are destroying the brain. Previously, we found that mice developing lupus-like disease contain antibodies that target certain cytoskeletal proteins involved in maintaining cell shape and protecting the cell. We are interested in understanding whether antibodies to the cytoskeletal protein MAP-2 (microtubule-associated protein-2) may be responsible for damaging the brain and adversely affecting behavior in mice. First we will determine when these antibodies are detected in diseased mice. This will provide important information regarding when antibodies first appear and how their presence relates to brain damage and altered behavior. Next, in order to examine where these antibodies bind, they will be applied to different structures in brains from healthy lupus-prone mice. This will establish whether antibodies to MAP-2 bind in specific regions or diffusely throughout the brain. Lastly, to determine whether these anti-MAP-2 antibodies actually damage the brain, they will be administered directly into the brain of healthy mice. This will provide conclusive evidence whether antibodies to MAP-2 are indeed destroying the brain and causing behavioral dysfunction. These experiments aim to provide a better understanding of the mechanisms underlying neurologic and psychiatric problems in SLE patients. Such knowledge may help in designing novel treatments for SLE and other behavioral disorders.
Competitiondate
201002
Approvedterm2
1 yr 0 mth
Pinamesdelim
Kapadia, Minesh
Approvedterm
1 an 0 mois
Cihrcontribution2
~ $17,500~ $0~